SynerGene Therapeutics, Inc. Report issue

For profit Phase 1 Phase 2
Founded: Potomac MD United States (1998)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2008
NCT00470613
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

SynerGene Therapeutics, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Central Nervous System Neoplasms (Phase 1)

Glioblastoma (Phase 2)

Neoplasms (Phase 1)

Pancreatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 9